Marianne Mancini is the Chief Operating Officer of Viking Therapeutics, Inc., a biotechnology company where she focuses on clinical operations and drug development for metabolic diseases. With over 30 years of experience in the pharmaceutical industry, she has held various...

Marianne Mancini is the Chief Operating Officer of Viking Therapeutics, Inc., a biotechnology company where she focuses on clinical operations and drug development for metabolic diseases. With over 30 years of experience in the pharmaceutical industry, she has held various key positions leading clinical trials and managing projects. She joined Viking in 2015 as the Vice President of Clinical Operations before becoming COO in 2021. Marianne holds advanced degrees in Bioethics and Business, showing her dedication to both the science and ethics in medicine. Her compensation package reflects her value to the company, including a significant salary and bonuses based on company performance, with total compensation reaching $3.51 million in 2023. Interestingly, her stock holdings have seen significant growth recently, particularly as the company advances its pipeline of clinical trials. Under her leadership, Viking is making strides in clinical research aimed at helping patients with serious health conditions. This forward momentum is evident in her recent performance metrics and the strategic direction she brings to Viking’s operations.